Study guide
5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis
Key Takeaways Explain This Topic AI
In purulent skin and soft tissue infections (abscesses, furuncles), incision and drainage (I&D) is the primary definitive therapy; adjunctive antimicrobials are indicated only with extensive surrounding cellulitis, systemic toxicity, age <6 months, or immunocompromise.
Clindamycin is an effective oral/IV agent for pediatric CA-MRSA only if the D-zone test is negative; a positive D-test indicates inducible macrolide-lincosamide-streptogramin B (iMLSb) resistance encoded by the erm gene, leading to rapid clinical failure under clindamycin therapy.
Trimethoprim-sulfamethoxazole (dosed 8-12 mg/kg/day of TMP component divided BID) provides potent CA-MRSA activity but lacks dependable activity against Streptococcus pyogenes (Group A Strep) due to extracellular thymidine salvage, precluding its use as monotherapy for non-purulent cellulitis.
Kingella kingae is a prominent cause of septic arthritis and osteomyelitis in children younger than 4 years; it is intrinsically resistant to clindamycin and vancomycin, requiring empiric coverage with a beta-lactam (cefazolin, ampicillin, or ceftriaxone).
Transition from IV to oral therapy in uncomplicated pediatric acute hematogenous osteomyelitis (AHO) is indicated when the patient is afebrile for 24-48 hours, exhibits clinical symptom improvement, and achieves a >=50% reduction in CRP from peak, with total duration of 3-4 weeks for AHO and 2-3 weeks for septic arthritis.
Last updated: September 2026
5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis
Quick Answer: Pediatric purulent SSTIs (abscesses) require incision and drainage (I&D) as primary therapy, with antibiotics reserved for surrounding cellulitis, systemic symptoms, or age <6 months. When treating suspected CA-MRSA, clindamycin (30–40 mg/kg/day) is effective only if the D-zone test is negative (ruling out inducible i MLS B i\text{MLS}_B i MLS B resistance). TMP-SMX (8–12 mg/kg/day TMP component BID) covers MRSA but fails to cover Group A Streptococcus (GAS) ; doxycycline (4 mg/kg/day BID) is safe for short courses (≤21 days) regardless of age per updated AAP guidance. For osteomyelitis and septic arthritis in children <4 years, always include a beta-lactam (cefazolin) because Kingella kingae is intrinsically resistant to clindamycin and vancomycin . Transition to oral therapy once afebrile for 24–48 hours with ≥50% CRP reduction , treating for 3–4 weeks (osteomyelitis) or 2–3 weeks (septic arthritis).
1. Pediatric SSTIs: Non-Purulent vs Purulent Infections
The Infectious Diseases Society of America (IDSA) guidelines categorize skin and soft tissue infections (SSTIs) into non-purulent and purulent forms to streamline pathogen prediction and antimicrobial selection. +-----------------------------------------------------------------------------------------+
- | Pediatric SSTI Classification & Management Algorithm |
- +-----------------------------------------------------------------------------------------+
- | Feature | Non-Purulent (Cellulitis, Erysipelas) | Purulent (Abscess, Carbuncle, Furuncle)|
- |----------------------|---------------------------------------|---------------------------------------|
- | Predominant Pathogen | Streptococcus pyogenes (GAS) > MSSA | Community-Acquired MRSA (CA-MRSA) > |
- | | | MSSA |
- | Clinical Signs | Diffuse spreading erythema, warmth, | Fluctuant, tender erythematous nodule |
- | | edema, induration, NO fluctuance/pus | with purulent collection / drainage |
- | Primary Intervention | Systemic Antimicrobials | INCISION AND DRAINAGE (I&D) |
- | Mild / Outpatient Rx | Cephalexin: 50-100 mg/kg/day div TID | I&D ALONE if simple/small (<2 cm) and |
- | | Cefadroxil: 30 mg/kg/day div BID | afebrile. If antibiotics indicated: |
- | | Amox-clav: 45-90 mg/kg/day div BID | Clindamycin OR TMP-SMX |
- | Severe / Inpatient Rx| Cefazolin: 50-100 mg/kg/day div Q8H | I&D + IV Vancomycin (40-60 mg/kg/d) |
- | | Ampicillin-sulbactam: 150-200 mg/kg/d | OR IV Clindamycin (30-40 mg/kg/d) |
- +-----------------------------------------------------------------------------------------+
- The Incision and Drainage (I&D) Mandate
In purulent cutaneous abscesses, the primary determinant of cure is adequate mechanical evacuation of pus . Randomized controlled trials in children demonstrate that for small, uncomplicated abscesses (<2 cm in diameter) without surrounding erythema or systemic signs, I&D alone without antibiotics yields cure rates >90% . Antibiotics do not penetrate the necrotic, acidic, hypoperfused center of an intact abscess.
Indications for Adjunctive Antimicrobial Therapy After I&D
Systemic antibiotics should be added to I&D when any of the following are present:
Severe or extensive disease (multiple sites of infection, abscess diameter ≥5 cm, or extensive surrounding cellulitis).
Rapid progression or signs of systemic illness (fever, tachycardia, tachypnea, hypotension, toxicity).
Patient age younger than 6 months (immature immune defenses and high risk of bacteremia).
High-risk anatomical areas (face, hands, feet, perineum, genitalia) or areas difficult to drain.
Associated septic thrombophlebitis or lack of response to I&D alone after 48 hours.
Significant underlying host comorbidities (immunodeficiency, neutropenia, diabetes mellitus).
2. CA-MRSA Pharmacotherapy in Children
Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) typically harbors the small, mobile Staphylococcal Cassette Chromosome mec (SCC mec ) type IV or V element and frequently produces the Panton-Valentine Leukocidin (PVL) pore-forming cytotoxin. +-----------------------------------------------------------------------------------------+
- | Oral Antimicrobial Regimens for Pediatric CA-MRSA SSTIs |
- +-----------------------------------------------------------------------------------------+
- | Antimicrobial | Pediatric Dosing | Spectrum & Key Clinical Nuances |
- |-----------------|--------------------------------------|----------------------------------------|
- | Clindamycin | 30 to 40 mg/kg/day divided TID | Covers CA-MRSA & GAS. Inhibits toxin |
- | | (Max: 1800 mg/day; IV or oral) | production (PVL). MUST be D-test neg. |
- | TMP-SMX | 8 to 12 mg/kg/day TMP component | High CA-MRSA potency. ZERO dependable |
- | (Bactrim) | divided BID (Max: 320 mg TMP/day) | GAS coverage! Avoid in infants <2 mo. |
- | Doxycycline | 4 mg/kg/day divided BID | CA-MRSA potency. AAP approved for |
- | | (Max: 200 mg/day; age >=8 or <21 d) | short courses (<=21 days) at any age. |
- | Linezolid | <12 yr: 30 mg/kg/day divided Q8H | Complete MRSA & GAS coverage; toxin |
- | | >=12 yr: 20 mg/kg/day (600 mg) div Q12| inhibition. Risk of myelosuppression. |
- +-----------------------------------------------------------------------------------------+
- Clindamycin & The D-Zone Test Mechanics
Clindamycin binds the 50S ribosomal subunit to inhibit bacterial protein and toxin synthesis. Resistance in S. aureus occurs via two primary genetic mechanisms:
Efflux pump ( msrA gene) : Active pumping of 14- and 15-membered macrolides (erythromycin, azithromycin) out of the cell. The isolate tests erythromycin-resistant but clindamycin-susceptible . Because clindamycin is not a substrate for this efflux pump, the drug remains clinically effective ( D-zone test NEGATIVE ).
Ribosomal target modification ( erm gene) : The erm gene encodes an enzyme that methylates the 23S rRNA adenine residues on the 50S subunit, conferring cross-resistance to macrolides, lincosamides, and type B streptogramins ( i MLS B i\text{MLS}_B i MLS B ). In many isolates, this gene is inducible by erythromycin but not initially by clindamycin. Automated testing may report the isolate as clindamycin-susceptible . +-----------------------------------------------------------------------------------------+
- | D-Zone Test Interpretation & Action |
- +-----------------------------------------------------------------------------------------+
- | Erythromycin Disk | Clindamycin Disk | D-Zone Morphology | Phenotype & Action |
- |-------------------|------------------|--------------------|-----------------------------|
- | Resistant (R) | Susceptible (S) | Circular, circular | Efflux pump (msrA) |
- | | | zone of inhibition | D-Test NEGATIVE: Use Clinda |
- | Resistant (R) | Susceptible (S) | Blunted, flat zone | Inducible iMLSb (erm gene) |
- | | | resembling a "D" | D-Test POSITIVE: AVOID |
- | | | adjacent to Erythro| Clinda (Rapid failure risk) |
- +-----------------------------------------------------------------------------------------+
Board Exam Rationale: Under clindamycin monotherapy, an i MLS B i\text{MLS}_B i MLS B -positive strain undergoes spontaneous point mutations (at a rate of ∼ 10 − 7 \sim 10^{-7} ∼ 1 0 − 7 ) that convert inducible resistance into constitutive resistance, leading to rapid clinical treatment failure . If the D-test is positive, clindamycin is strictly contraindicated.
Trimethoprim-Sulfamethoxazole (TMP-SMX) & The GAS Coverage Void
TMP-SMX is dosed based on its trimethoprim component: 8 to 12 mg/kg/day divided every 12 hours . While TMP-SMX is highly active against CA-MRSA, it lacks reliable activity against Streptococcus pyogenes (Group A Streptococcus) in vivo . In infected, purulent tissues, S. pyogenes can utilize extracellular thymidine and purines released from lysed human leukocytes, completely bypassing the TMP-SMX block on tetrahydrofolic acid synthesis. Therefore, TMP-SMX should never be used as monotherapy for non-purulent cellulitis . If mixed MRSA and GAS infection is suspected, TMP-SMX must be combined with a beta-lactam (e.g., cephalexin).
Doxycycline in Pediatrics: The Removal of the 8-Year Age Restriction
Tetracyclines historically carried a black-box contraindication in children younger than 8 years due to permanent dental staining and enamel hypoplasia. However, extensive pediatric research and updated American Academy of Pediatrics (AAP) Red Book guidance establish that doxycycline binds calcium far less avidly than older tetracyclines (tetracycline, minocycline). Multiple prospective studies demonstrated that short courses (≤21 days) of doxycycline do NOT cause dental discoloration or enamel defects in children under 8 years. Doxycycline (4 mg/kg/day divided BID, max 200 mg/day) is endorsed for short-term CA-MRSA or tick-borne infections across all pediatric age cohorts.
3. Pediatric Acute Hematogenous Osteomyelitis (AHO) & Septic Arthritis
Musculoskeletal infections in children are predominantly hematogenous in origin. Sluggish, turbulent capillary loops in the metaphyses of growing long bones (femur, tibia, humerus) create a fertile nidus for bacterial deposition and micro-infarction. +-----------------------------------------------------------------------------------------+
- | Microbiology of Pediatric Osteomyelitis & Septic Arthritis |
- +-----------------------------------------------------------------------------------------+
- | Age Group | Predominant Pathogens | Clinical & Microbiological Pearls |
- |---------------------------|---------------------------------|-----------------------------------|
- | All pediatric ages | Staphylococcus aureus | Most common overall (>70-80%). |
- | | (MSSA and CA-MRSA) | PVL+ strains cause severe osteo. |
- | Children < 4 years | Kingella kingae | Fastidious Gram-negative coccobacillus|
- | (Especially 6 to 36 mo) | | INTRINSICALLY RESISTANT to |
- | | | clindamycin and vancomycin! |
- | All ages | Streptococcus pyogenes (GAS) | Highly destructive, high CRP. |
- | Sickle Cell Disease | Salmonella species & S. aureus | Bone marrow microvascular hypoxia |
- | | | predisposes to Salmonella seeding.|
- | Neonates (< 1 month) | Group B Strep, E. coli, MSSA/MRSA| High rate of concomitant arthritis|
- +-----------------------------------------------------------------------------------------+
- The Infant Transphyseal Bridge
In infants younger than 18 months , transphyseal blood vessels penetrate the cartilaginous growth plate, bridging the metaphysis directly to the epiphysis and the intra-articular joint space. Consequently, acute hematogenous osteomyelitis in infants frequently decompresses directly into the joint space, resulting in concurrent septic arthritis and permanent epiphyseal plate damage.
Kingella kingae: The Stealth Pathogen of Toddlers
Kingella kingae colonizes the respiratory tract and translocates into bones and joints in toddlers aged 6 months to 4 years :
Clinical Presentation : Often subacute and insidious—mild limp, joint swelling, low-grade or absent fever, and modest elevations in inflammatory markers (ESR, CRP).
Culture-Negative Arthritis : K. kingae is fastidious and does not grow well on standard solid agar; clinical diagnosis requires inoculating synovial fluid directly into blood culture vials or performing specific real-time PCR or 16S rRNA assays.
Pharmacological Achilles Heel : Kingella kingae is intrinsically resistant to both clindamycin and vancomycin! However, it is exquisitely susceptible to beta-lactams (ampicillin, cefazolin, cephalexin, ceftriaxone). If a toddler with septic arthritis is treated with vancomycin or clindamycin alone, K. kingae will not be treated, resulting in clinical failure.
4. Empiric Regimens, Transition Criteria & Durations for AHO +-----------------------------------------------------------------------------------------+
- | Empiric IV Antimicrobial Selection for AHO / Septic Arthritis |
- +-----------------------------------------------------------------------------------------+
- | Clinical Scenario | Empiric Parenteral Regimen |
- |------------------------------------------|----------------------------------------------|
- | Age >=4 yr, Low Local MRSA (<10-15%) | Cefazolin: 100-150 mg/kg/day divided Q8H |
- | | (Max: 6000 mg/day or 6 g/day) |
- | Age >=4 yr, High Local MRSA (>=10-15%) | Vancomycin: 60 mg/kg/day divided Q6-8H |
- | or Septic Presentation | OR Clindamycin: 40 mg/kg/day divided Q8H |
- | Age <4 years (MUST cover Kingella kingae)| Cefazolin PLUS Vancomycin (or Clindamycin) |
- | | OR Ampicillin-sulbactam: 150-200 mg/kg/d Q6H |
- | Sickle Cell Disease (Salmonella + MRSA) | Ceftriaxone: 50-75 mg/kg/d once daily PLUS |
- | | Vancomycin: 60 mg/kg/day divided Q6-8H |
- +-----------------------------------------------------------------------------------------+
- Evidence-Based IV-to-Oral Transition Criteria
Pediatric Infectious Diseases Society (PIDS) and IDSA guidelines strongly recommend early transition from IV to oral antimicrobials rather than placing peripherally inserted central catheters (PICCs) for prolonged outpatient parenteral antibiotic therapy (OPAT), which carries high rates of mechanical malfunction, thrombosis, and catheter infections. +-----------------------------------------------------------------------------------------+
- | PIDS/IDSA Criteria for Early IV-to-Oral Step-Down |
- +-----------------------------------------------------------------------------------------+
- | Criterion 1 | Afebrile for at least 24 to 48 hours without antipyretics. |
- | Criterion 2 | Significant clinical improvement: resolving pain, swelling, warmth, and |
- | | restoration of limb motion or weight-bearing ability. |
- | Criterion 3 | Objective biomarker reduction: C-reactive protein (CRP) has decreased by |
- | | AT LEAST 50% from the peak baseline value. |
- | Criterion 4 | Patient can swallow, retain, and absorb high-dose oral medications. |
- | Criterion 5 | An appropriate oral agent with proven pathogen susceptibility exists. |
- +-----------------------------------------------------------------------------------------+
- Oral Step-Down Regimens & Durations
MSSA / K. kingae : High-dose oral cephalexin (100–150 mg/kg/day divided TID or QID, max 4 g/day).
CA-MRSA : High-dose oral clindamycin (30–40 mg/kg/day divided TID, if D-test negative) OR oral linezolid .
K. kingae (confirmed) : Oral amoxicillin (80–90 mg/kg/day divided TID) or cephalexin.
Treatment Durations :
Uncomplicated Acute Hematogenous Osteomyelitis : 3 to 4 weeks total (IV + oral combined).
Uncomplicated Septic Arthritis : 2 to 3 weeks total (IV + oral combined).
Complicated Osteomyelitis (subperiosteal abscess, chronic osteo, surgical debridements): ≥6 weeks .